PCG
AZN icon

Prosperity Consulting Group’s AstraZeneca AZN Stock Holding History

Prosperity Consulting Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$527K Buy
2,674
+714
+36% +$138K 0.02% 351
2025
Q4 		$360K Buy
1,960
+371
+23% +$65.1K 0.02% 409
2025
Q3 		$244K Buy
+1,589
New +$240K 0.01% 454

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Prosperity Consulting Group's AZN Position: Q1 2026 in Review

Prosperity Consulting Group increased its AstraZeneca (AZN) stake by 36% in Q1 2026, buying an estimated $138K and bringing the position to 2,674 shares worth $527K. The position accounts for 0.02% of the portfolio, ranked #351.

Prosperity Consulting Group first reported a position in AZN in Q3 2025 and has held it in 3 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Prosperity Consulting Group held 2,674 shares of AstraZeneca worth $527K as of Q1 2026.
  • Prosperity Consulting Group bought 714 AstraZeneca shares in Q1 2026, an estimated $138K.
  • AstraZeneca made up 0.02% of Prosperity Consulting Group's portfolio in Q1 2026, its #351 holding.
  • Prosperity Consulting Group first reported a position in AstraZeneca in Q3 2025 and has held it in 3 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Prosperity Consulting Group's 13F filing for Q1 2026, filed 5 May 2026.